Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ALLO Company Profile and Key Details

NASDAQ : ALLO

Allogene Therapeutics, Inc.

$1.62
-0.01-0.61%
Open: 4:00 PM
63.69
BESG ScoreESG Rating

ALLO Stock Price Chart

Stock Price Today

Allogene Therapeutics, Inc. (ALLO) stock declined over -0.61%, trading at $1.62 on NASDAQ, down from the previous close of $1.63. The stock opened at $1.60, fluctuating between $1.53 and $1.64 in the recent session.

Stock Snapshot

1.63
Prev. Close
1.6
Open
351.97M
Market Cap
217.27M
Number of Shares
1.53
Day Low
1.64
Day High
-1.23
P/E Ratio
64.2%
Free Float in %
-1.32
EPS (TTM)
3.04
Book Value
-1.42
Cash Flow per Share
9.42M
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Mar 21, 20251.611.641.531.6210.02M
Mar 20, 20251.651.741.611.632.72M
Mar 19, 20251.691.731.531.695.27M
Mar 18, 20251.851.851.691.693.34M
Mar 17, 20251.941.951.821.852.64M
Mar 14, 20252.032.101.881.945.52M
Mar 13, 20252.042.091.841.891.98M
Mar 12, 20252.062.081.962.061.68M
Mar 11, 20252.092.121.872.032.8M
Mar 10, 20252.112.191.992.053.92M
Mar 07, 20252.052.322.042.184.7M
Mar 06, 20251.902.051.882.022.43M
Mar 05, 20251.911.951.851.932.3M
Mar 04, 20251.731.921.691.903.42M
Mar 03, 20251.851.941.751.804.02M
Feb 28, 20251.911.981.801.956.05M
Feb 27, 20252.022.111.931.952.19M
Feb 26, 20251.992.121.982.042.5M
Feb 25, 20252.112.151.921.993.51M
Feb 24, 20252.152.322.002.145.65M

Contact Details

South San Francisco, CA 94080

United States

Website: https://www.allogene.comContact: 650 457 2700

About Company

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Company Information

Employees226
Beta1.02
Sales or Revenue$95.00K
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Allogene Therapeutics, Inc. (ALLO) stock price?
Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $1.62 in the last trading session. During the trading session, ALLO stock reached the peak price of $1.64 while $1.53 was the lowest point it dropped to. The percentage change in ALLO stock occurred in the recent session was -0.61% while the dollar amount for the price change in ALLO stock was -$0.01.
ALLO's industry and sector of operation?
The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector. Allogene Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ALLO?
Mr. Arun Balakumaran M.D., Ph.D.
Chief Medical Officer
Dr. Alison Moore Ph.D.
Chief Technical Officer
Dr. Eric Thomas Schmidt Ph.D.
Executive Vice President & Chief Financial Officer
Mr. Veer Bhavnagri
Gen. Counsel & Compliance Officer
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Co-Founder & Executive Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Mr. Timothy L. Moore Ph.D.
Executive Vice President & Chief Technical Officer
Ms. Barbra Sasu
Chief Scientific Officer
Mr. Stephen Cheng
Chief Information Officer
Ms. Lillian Smith
Interim Gen. Counsel & Compliance Officer
Ms. Christine Cassiano
Chief Communications Officer
Ms. Susan R. Lundeen
Chief People Officer
Ms. Diane Hagerty
Senior Vice President of Quality
Dr. Rafael G. Amado M.D.
Pres and Head of Global Oncology R&D
How ALLO did perform over past 52-week?
ALLO's closing price is 22.73% higher than its 52-week low of $1.32 where as its distance from 52-week high of $4.63 is -65.01%.
How many employees does ALLO have?
Number of ALLO employees currently stands at 226.
Link for ALLO official website?
Official Website of ALLO is: https://www.allogene.com
How do I contact ALLO?
ALLO could be contacted at phone 650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.
How many shares of ALLO are traded daily?
ALLO stock volume for the day was 9.42M shares. The average number of ALLO shares traded daily for last 3 months was 5.53M.
What is the market cap of ALLO currently?
The market value of ALLO currently stands at $351.97M with its latest stock price at $1.62 and 217.27M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph